Philly Life Sciences Vacancy Holds at 27%
Greater Philadelphia's life sciences market showed a 27% vacancy rate in Q1 2026 as venture funding climbed.
Updated on Nov. 20, 2026 in Biotech

Live Poll
Should Pennsylvania spend more state money to attract life sciences companies?
Greater Philadelphia's 8.7 million square foot life sciences market had a 27% total vacancy rate in Q1 2026, down 0.2% year-over-year. Venture capital funding for Philly life sciences reached $2.2 billion in the first nine months of 2026, according to the extraction.
Why it matters
Philadelphia's lower rents, roughly 30% below Boston's, and rising venture investment may make the region more attractive to life sciences tenants for Philadelphia-area businesses. The market's gene and cell therapy focus and its rising funding levels suggest demand for lab space may keep shifting over the coming years.
The figures come from market vacancy and venture funding tracking for the region. Philadelphia's 27% vacancy rate sits below Boston's 33%, and its $2.2 billion in nine-month venture funding already exceeds 2025's full-year total of $1 billion, though the stub does not say how the rest of 2026 will unfold.
The players
Earendil Labs
A Wilmington-based company that raised roughly $800 million in Q1 2026 to scale its artificial intelligence program.
Brandywine
A real estate firm that began tracking life sciences leasing inquiries in the region in 2021.
The details
Brandywine began tracking life sciences leasing inquiries in 2021, when about 80 firms were looking at the Philadelphia market, a figure that has since fallen to about a dozen. Earendil Labs, based in Wilmington, raised roughly $800 million in Q1 2026 to scale its artificial intelligence program.
Timeline
2021: Brandywine began tracking life sciences leasing inquiries in the region.
Q1 2026: Greater Philadelphia's life sciences vacancy rate measured at 27%.
Q1 2026: Earendil Labs raised roughly $800 million for its AI program.
Q3 2026: Philadelphia life sciences received about $400 million in venture capital funding.
2026-2027 budget: Innovate 2.0 set aside $125 million for a life sciences fund.
The Big Picture
The vacancy figures reflect the aftermath of the pandemic-era boom, when some developers built speculative lab space that the sector's cooling leasing demand has not yet absorbed. Philadelphia's shrinking pool of leasing inquiries, down from about 80 firms in 2021 to about a dozen, signals how quickly that demand has contracted.
Philadelphia's rents for life sciences tenants run roughly 30% below Boston's, a gap that may matter to startups deciding where to lease lab space. Companies weighing a move should compare current asking rents and available space, since the 27% vacancy rate means there is room to negotiate.
The takeaway
Philadelphia's lower rents and growing venture funding give the region a competitive position in life sciences, but its shrinking leasing demand shows the market has not yet recovered from its pandemic-era peak.
Further reading
For more on the sector's funding picture, explore Biotech coverage on Wisevoter.
Source note: This article includes information reported by Bisnow.
Live Poll
Should Pennsylvania spend more state money to attract life sciences companies?






